TH and DCX mRNAs in peripheral blood and bone marrow predict outcome in metastatic neuroblastoma patients

详细信息    查看全文

• 作者：Yania Yáñez ; David Hervás ; Elena Grau…
• 关键词：Neuroblastoma ; Minimal residual disease ; Reverse transcriptase quantitative polymerase chain reaction (RT ; qPCR) ; TH ; DCX
• 刊名：Journal of Cancer Research and Clinical Oncology
• 出版年：2016
• 出版时间：March 2016
• 年：2016
• 卷：142
• 期：3
• 页码：573-580
• 全文大小：1,027 KB
• 参考文献：Ambros IM, Benard J, Boavida M, Bown N, Caron H, Combaret V, Couturier J, Darnfors C, Delattre O, Freeman-Edward J, Gambini C, Gross N, Hattinger CM, Luegmayr A, Lunec J, Martinsson T, Mazzocco K, Navarro S, Noguera R, O’Neill S, Potschger U, Rumpler S, Speleman F, Tonini GP, Valent A, Van Roy N, Amann G, De Bernardi B, Kogner P, Ladenstein R, Michon J, Pearson AD, Ambros PF (2003) Quality assessment of genetic markers used for therapy stratification. J Clin Oncol 21(11):2077–2084CrossRef PubMed
  Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM (1984) Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224:1121–1124CrossRef PubMed
  Burchill SA, Lewis IJ, Abrams KR et al (2001) Circulating neuroblastoma cells detected by reverse transcriptase polymerase chain reaction for tyrosine hydroxylase mRNA are an independent poor prognostic indicator in stage 4 neuroblastoma in children over 1 year. J Clin Oncol 19:1795–1801PubMed
  Burgues O, Navarro S, Noguera R, Pellín A, Ruiz A, Castel V, Llombart-Bosch A (2006) Prognostic value of the international neuroblastoma pathology classification in neuroblastoma (Schwannian stroma-poor) and comparison with other prognostic factors: a study of 182 cases from the Spanish Neuroblastoma Registry. Virchows Arch 449(4):410–420CrossRef PubMed
  Cheung IY, Lo Piccolo MS, Kushner BH et al (2003) Early molecular response of marrow disease to biologic therapy is highly prognostic in neuroblastoma. J Clin Oncol 21:3853–3858CrossRef PubMed
  Cheung IY, Feng Y, Gerald W et al (2008) Exploiting gene expression profiling to identify novel minimal residual disease markers of neuroblastoma. Clin Cancer Res 14:7020–7027PubMedCentral CrossRef PubMed
  Cheung NK, Ostrovnaya I, Kuk D, Cheung IY (2015) Bone marrow minimal residual disease was an early response marker and a consistent independent predictor of survival after anti-GD2 immunotherapy. J Clin Oncol 33(7):755–763CrossRef PubMed
  Corrias MV, Faulkner LB, Pistorio A, Rosanda C, Callea F, Lo Piccolo MS, Scaruffi P, Marchi C, Lacitignola L, Occhino M, Gambini C, Tonini GP, Haupt R, De Bernardi B, Pistoia V, Garaventa A (2004) Detection of neuroblastoma cells in bone marrow and peripheral blood by different techniques: accuracy and relationship with clinical features of patients. Clin Cancer Res 10:7978–7985CrossRef PubMed
  Corrias MV, Haupt R, Carlini B, Cappelli E, Giardino S, Tripodi G, Tonini GP, Garaventa A, Pistoia V, Pistorio A (2012) Multiple target molecular monitoring of bone marrow and peripheral blood samples from patients with localized neuroblastoma and healthy donors. Pediatr Blood Cancer 58(1):43–49CrossRef PubMed
  Hartomo TB, Kozaki A, Hasegawa D, Van Huyen Pham T, Yamamoto N, Saitoh A, Ishida T, Kawasaki K, Kosaka Y, Ohashi H et al (2012) Minimal residual disease monitoring in neuroblastoma patients based on the expression of a set of real-time RT-PCR markers in tumor-initiating cells. Oncol Rep 29:1629–1636
  Kuçi Z, Seitz G, Kuçi S, Kreyenberg H, Schumm M, Lang P, Niethammer D, Handgretinger R, Bruchelt G (2006) Pitfalls in detection of contaminating neuroblastoma cells by tyrosine hydroxylase RT-PCR due to catecholamine-producing hematopoietic cells. Anticancer Res 26(3A):2075–2080PubMed
  Lampert F, Rudolph B, Christiansen H, Franke F (1988) Identical chromosome 1p breakpoint abnormality in both the tumor and the constitutional karyotype of a patient with neuroblastoma. Cancer Genet Cytogenet 34:235–239CrossRef PubMed
  Lode HN, Bruchelt G, Seitz G, Gebhardt S, Gekeler V, Niethammer D, Beck J (1995) Reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of monoamine transporters in neuroblastoma cell lines: correlations to meta-iodobenzylguanidine (MIBG) uptake and tyrosine hydroxylase gene expression. Eur J Cancer 31A(4):586–590CrossRef PubMed
  London WB, Castleberry RP, Matthay KK, Look AT, Seeger RC, Shimada H, Thorner P, Brodeur G, Maris JM, Reynolds CP, Cohn SL (2005) Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children’s Oncology Group. J Clin Oncol 23:6459–6465CrossRef PubMed
  Look AT, Hayes FA, Shuster JJ, Douglass EC, Castleberry RP, Bowman LC, Smith EI, Brodeur GM (1991) Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 9:581–591PubMed
  Monclair T, Brodeur GM, Ambros PF, Brisse HJ, Cecchetto G, Holmes K, Kaneko M, London WB, Matthay KK, Nuchtern JG, von Schweinitz D, Simon T, Cohn SL, Pearson AD, Force IT (2009) The International Neuroblastoma Risk Group (INRG) staging system: an INRG task force report. J Clin Oncol 27:298–303PubMedCentral CrossRef PubMed
  Noguera R, Canete A, Pellin A, Ruiz A, Tasso M, Navarro S, Castel V, Llombart-Bosch A (2003) MYCN gain and MYCN amplification in a stage 4S neuroblastoma. Cancer Genet Cytogenet 140(2):157–161CrossRef PubMed
  Oltra S, Martinez F, Orellana C, Grau E, Fernandez JM, Canete A, Castel V (2005) The doublecortin gene, a new molecular marker to detect minimal residual disease in neuroblastoma. Diagn Mol Pathol 14(1):53–57CrossRef PubMed
  Royston P, Altman DG, Sauerbrei W (2006) Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med 25(1):127–141CrossRef PubMed
  Sakamoto Y, Ishiguro M, Kitagawa G (1986) Akaike information criterion statistics. D. Reidel Publishing Company, Dordrecht
  Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B, Stram DO, Gerbing RB, Lukens JN, Matthay KK, Castleberry RP (1999) The international neuroblastoma pathology classification (the Shimada system). Cancer 86:364–372CrossRef PubMed
  Spitz R, Oberthuer A, Zapatka M, Brors B, Hero B, Ernestus K, Oestreich J, Fischer M, Simon T, Berthold F (2006) Oligonucleotide array-based comparative genomic hybridization (aCGH) of 90 neuroblastomas reveals aberration patterns closely associated with relapse pattern and outcome. Genes Chromosomes Cancer 45:1130–1142CrossRef PubMed
  Stutterheim J, Gerritsen A, Zappeij-Kannegieter L et al (2008) PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastoma. J Clin Oncol 26:5443–5449CrossRef PubMed
  Stutterheim J, Zappeij-Kannegieter L, Versteeg R et al (2011) The prognostic value of fast molecular response of marrow disease in patients aged over 1 year with stage 4 neuroblastoma. Eur J Cancer 47:1193–1202CrossRef PubMed
  Träger C, Vernby A, Kullman A, Ora I, Kogner P, Kågedal B (2008) mRNAs of tyrosine hydroxylase and dopa decarboxylase but not of GD2 synthase are specific for neuroblastoma minimal disease and predicts outcome for children with high-risk disease when measured at diagnosis. Int J Cancer 123:2849–2855CrossRef PubMed
  Viprey VF, Gregory WM, Corrias MV, Tchirkov A, Swerts K, Vicha A, Dallorso S, Brock P, Luksch R, Valteau-Couanet D, Papadakis V, Laureys G, Pearson AD, Ladenstein R, Burchill SA (2014) Neuroblastoma mRNAs predict outcome in children with stage 4 neuroblastoma: a European HR-NBL1/SIOPEN Study. J Clin Oncol 32:1074–1083CrossRef PubMed
  Yáñez Y, Grau E, Oltra S, Cañete A, Martínez F, Orellana C, Noguera R, Palanca S, Castel V (2011) Minimal disease detection in peripheral blood and bone marrow from patients with non-metastatic neuroblastoma. J Cancer Res Clin Oncol 137(8):1263–1272CrossRef PubMed
  
• 作者单位：Yania Yáñez (1)
  David Hervás (2)
  Elena Grau (1)
  Silvestre Oltra (3)
  Gema Pérez (4)
  Sarai Palanca (4)
  Mar Bermúdez (5)
  Catalina Márquez (6)
  Adela Cañete (1)
  Victoria Castel (1)
  
  1. Unidad de Oncología Pediátrica, Hospital La Fe, Avda. Fernando Abril Martorell, 106, 46026, Valencia, Spain
  2. Unidad de Bioestadística, Hospital La Fe, Valencia, Spain
  3. Unidad de Genética y Diagnóstico Prenatal, Hospital La Fe, Valencia, Spain
  4. Laboratorio de Biología Molecular, Hospital La Fe, Valencia, Spain
  5. Servicio de Oncología Pediátrica, Hospital Virgen de la Arrixaca, Murcia, Spain
  6. Servicio de Oncología Pediátrica, Hospital Virgen del Rocio, Seville, Spain
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Oncology
  Cancer Research
  Internal Medicine
  Hematology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1432-1335

文摘

Purpose In metastatic neuroblastoma (NB) patients, accurate risk stratification and disease monitoring would reduce relapse probabilities. This study aims to evaluate the independent prognostic significance of detecting tyrosine hydroxylase (TH) and doublecortin (DCX) mRNAs by reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) in peripheral blood (PB) and bone marrow (BM) samples from metastatic NB patients.